Organon & Co. reported results for the 2026 quarter, with revenue of $1.56B, net income of $108M and diluted EPS of $0.4, against $1.59B, $145M and $0.56 in the prior-year quarter, respectively.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$1.56B$1.59B(2.3%) | Net income²$108M$145M(25.5%) | Diluted EPS³$0.4$0.56(28.6%) |
¹ Reported as “Revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Definitive agreement reached to be acquired by Sun Pharma for $14.00 per share; stockholder approval received and closing expected in early 2027.
- Worldwide sales declined roughly 2% in Q2 and 3% year-to-date 2026; foreign exchange had a positive impact (about 3% in Q2 and 4% YTD).
- Brand performance mixed: strong growth for Hadlima, Emgality and Zetia/Vytorin; notable declines in Nexplanon, Singulair, Ontruzant and Jada.
- Commercial changes included divestiture of the Jada System, expanded Samsung biosimilars commercialization rights, and $30M in fixed commitments paid.
- Company is executing restructuring and supply-chain separations, recognizing $31M of restructuring charges year-to-date and advancing manufacturing and network optimization.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.